Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

48.98 +0.72 (+1.49%)
Streaming Delayed Price Updated: 12:09 PM EST, Nov 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
99 100 Next >
News headline image
NOVO NORDISK A/S (NYSE: NVO) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Novo Nordisk A/S Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
FDA Approves Sanofi's Merilog As First Rapid-Acting Insulin Biosimilar Product For Diabetes ↗
Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management. 
Via Benzinga
News headline image
These 3 Stocks Just Announced Major Dividend Hikes
Via MarketBeat
News headline image
Novo Nordisk Shares Near New 52-Week Low: Analysts See Big Upside
Novo Nordisk shares are closing in on a new 52-week low. Is the stock gearing up for a recovery with sentiment currently low? 
Via MarketBeat
News headline image
2 Important Insights From Novo Nordisk's Earnings Call ↗
Via The Motley Fool
News headline image
A Closer Look at Novo Nordisk's Options Market Dynamics ↗
 
Via Benzinga
News headline image
How Is The Market Feeling About Novo Nordisk? ↗
 
Via Benzinga
News headline image
NVO STOCK NEWS: NVO Shareholders with Large Losses Should Contact Robbins LLP for Information About the Class Action Lawsuit Against Novo Nordisk A/S
From Robbins LLP
Via GlobeNewswire
News headline image
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action – NVO
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Lowey Dannenberg Notifies Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $200,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
News headline image
Why Novo Nordisk Stock Keeps Going Down ↗
Via The Motley Fool
News headline image
Is Novo Nordisk Stock a Buy Now? ↗
Via The Motley Fool
News headline image
Novo Nordisk Beat Expectations in Q4 and a Huge Catalyst Could Be Coming Soon ↗
Via The Motley Fool
News headline image
Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday? ↗
Ascendis Pharma beat Q4 earnings and revenue estimates, driven by a $100M Novo Nordisk deal and Yorvipath's EU launch. Goldman Sachs raised its price target. 
Via Benzinga
News headline image
Will Eli Lilly Stock Keep Climbing? Q2 Trial Results Are Crucial
Eli Lilly is still seeing rapid sales growth for its diabetes and weight loss drugs. However, one drug waiting in the wings hopes to be its next blockbuster. 
Via MarketBeat
News headline image
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
What the Options Market Tells Us About Novo Nordisk ↗
 
Via Benzinga
News headline image
GLP-1 Alternatives: 2 Stocks Benefiting From Weight Loss Trends
GLP-1 weight loss drugs are in short supply enabling lab to make compounded GLP-1 treatments sold for 80% less than the name-brand drugs. 
Via MarketBeat
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against TELUS International, Novo Nordisk, Micron, and ModivCare and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
NOVO NORDISK A/S (NYSE: NVO) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Novo Nordisk A/S Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
Why Hims & Hers Health Stock Crushed Novo Nordisk and Viking Therapeutics Today ↗
Via The Motley Fool
News headline image
Hims & Hers Takes Aim At Big Pharma In Controversial Super Bowl Ad — Retail Loves The Fight ↗
The commercial aired Sunday night on Fox and positioned obesity as "America's deadliest epidemic" while criticizing the $160 billion weight-loss industry and the broader healthcare system. 
Via Stocktwits
News headline image
NYSE:NVO is showing good growth, while it is not too expensive. ↗
NYSE:NVO is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced. 
Via Chartmill
News headline image
NVO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action – NVO
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Lowey Dannenberg Notifies Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $200,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
News headline image
IBD 50 Stock Hims & Hers Faces Backlash Over Provocative Super Bowl Ad ↗
Shares rocketed on Friday, but the company might not be out of hot water yet. 
Via Investor's Business Daily
News headline image
Novo Nordisk Eyes 2025 Regulatory Filing For Hemophilia Candidate After Encouraging Pediatric Study Data ↗
Novo Nordisk's phase 3 trial of Mim8 in children with hemophilia A showed a 0.53 mean annualized bleeding rate, with 74.3% reporting zero treated bleeds. 
Via Benzinga
News headline image
We Asked Retail Traders About Eli Lilly’s Biggest Post-Q4 Risk — Most Say It’s The Weight-Loss Drug Wars ↗
Lilly’s fiercest competitor in the obesity market is Novo Nordisk, which offers Ozempic and Wegovy. However, rising threats from other players such as Hims & Hers, Amgen, and Viking Therapeutics also... 
Via Stocktwits
News headline image
Mark Cuban Calls Out Elon Musk's Growing Influence Under Trump: 'On A Mission To Make Himself...Above And Beyond The President Of The United States' ↗
Introduction: In a recent tweet, billionaire entrepreneur Mark Cuban raised questions about Elon Musk's intentions and his control over free speech, stirring a debate on the tech mogul's influence. 
Via Benzinga
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.